Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
INAYA Capital is a venture capital firm founded with a focus on the MedTech sector. Established in the United States, the firm partners with innovators to develop medical technologies that are clinically relevant and economically viable. INAYA Capital aims to support the evolution of healthcare through specialized investments in medical devices, tools and diagnostics, and digital health.
The firm operates with a stage-agnostic investment approach, primarily focusing on early-stage companies from Seed to Series B. INAYA Capital has a notable history of backing advancements in the MedTech space, with several portfolio companies achieving significant exits through acquisitions by major firms such as Johnson & Johnson, Boston Scientific, Abbott, and Covidien.
Currently, INAYA Capital's team consists of experienced professionals with backgrounds in medicine and entrepreneurship, enhancing their ability to assess and support innovative healthcare solutions. The firm is committed to bridging gaps in capital formation and ecosystem depth within the MedTech sector.
INAYA Capital invests in the MedTech sector, emphasizing therapeutic areas with significant and rising human burden. Their investment strategy is grounded in disciplined capital deployment, focusing on problem-solution alignment, defensible science, and a clear path to clinical validation. The firm assesses opportunities based on reimbursement logic, adoption dynamics, and sustainable economics.
Targeting early-stage companies, INAYA Capital employs a stage-agnostic approach, primarily focusing on Seed to Series B investments. The firm seeks to partner with companies that demonstrate a strong potential for clinical relevance and economic value. Their investment criteria include a thorough evaluation of the technology's ability to address significant clinical needs, as well as its market viability.
INAYA Capital has backed several notable MedTech advancements, including companies that have been acquired by major firms such as Johnson & Johnson, Boston Scientific, Abbott, and Covidien. Specific portfolio companies include:
These companies represent a fraction of INAYA Capital's commitment to advancing healthcare through strategic investments in the MedTech sector.
Ashkan Haghighat, PhD - General Partner. Ashkan has extensive experience in venture capital and a strong background in the MedTech sector.
Guy Leclerc, MD - Interventional Cardiologist, CEO/Founder of Accelab, Advisor. Guy brings a wealth of medical expertise and industry insights to the firm.
William Hunter, MD - CEO of Canary Medical and Angiotech, Advisor. William has a proven track record in leading successful MedTech companies.
Amr Salahieh - CEO of Shifamed LLC, Advisor. Amr is known for his innovative approaches in the MedTech space.
Lori Chmura - CEO of Nyra Medical, Advisor. Lori leads Nyra Medical with a focus on developing cutting-edge medical solutions.
To pitch to INAYA Capital, founders should visit their website at inayacapital.com. The firm prefers detailed pitch decks that include information on the technology's clinical relevance, economic value, and market strategy. Founders should be prepared for a thorough evaluation process, as INAYA Capital emphasizes disciplined capital deployment.
Response times may vary, but founders can expect to receive feedback on their submissions. Warm introductions are encouraged to enhance the likelihood of engagement.
INAYA Capital has been actively supporting the evolution of healthcare through specialized investments in MedTech. They have backed several notable advancements in the sector, including companies that have been acquired by major firms such as Johnson & Johnson and Boston Scientific.
Recent activity includes continued investments in early-stage MedTech companies, with a focus on those addressing significant clinical needs and demonstrating economic viability. The firm remains committed to bridging gaps in capital formation and enhancing the operational capabilities of its portfolio companies.
What are INAYA Capital's investment criteria?
INAYA Capital focuses on early-stage investments in the MedTech sector, particularly in companies that address significant clinical needs and demonstrate economic viability. They assess opportunities based on problem-solution alignment, defensible science, and a clear path to clinical validation.
How can I pitch to INAYA Capital?
Founders interested in pitching to INAYA Capital should visit their website at inayacapital.com for more information on the application process. They prefer detailed pitches that outline the clinical relevance and economic value of the proposed technology.
What makes INAYA Capital different from other venture firms?
INAYA Capital provides more than just capital; they offer industry access, strategic guidance, and operational insights to their portfolio companies. This active involvement helps bridge gaps in capital formation and enhances the overall value of their investments.
What is the geographic focus of INAYA Capital?
INAYA Capital primarily invests in the United States, targeting early-stage MedTech companies that are positioned to make a significant impact in the healthcare sector.
What is the typical check size for investments?
While specific check sizes are not disclosed, INAYA Capital focuses on early-stage investments, typically ranging from Seed to Series B funding rounds.
What is INAYA Capital's post-investment involvement like?
INAYA Capital actively engages with its portfolio companies, providing strategic guidance and operational support to help them navigate the complexities of the MedTech industry.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.